PODD — Insulet Corp.

Sentiment is decisively negative as of 2026-09-13. The Q2 2026 print (Aug 5) beat on the top line, but the FY2026 U.S. growth guidance cut to 17–19% — driven by weaker-than-expected Type 2 utilization and retention — triggered a wave of sell-side downgrades and target cuts from JPMorgan, Leerink, BTIG and TD Cowen, with consensus price targets compressing to roughly $172–$195 (FMP consensus: $185.18). High-profile institutional exits (Artisan Partners) added to the overhang, and lingering shareholder class actions tied to earlier voluntary medical device corrections froze the multiple. The tape confirms the mood: -10.5% in one week, -40.0% in six months, sitting just above the 52-week low. The one bullish datapoint — CEO Ashley McEvoy buying ~$160,000 of stock in late August — is being ignored so far.

Revenue has compounded impressively over three years — from $432.7M in Q3 2023 to $801.7M in Q2 2026 — but the growth rate is now clearly decelerating, and that deceleration is the whole story. YoY revenue growth ran +28.8% (Q1 2025), +32.9% (Q2 2025), +29.9% (Q3 2025), +31.2% (Q4 2025), +33.9% (Q1 2026) — then dropped to +23.5% in Q2 2026. That is a real step-down of roughly 10 points, not noise, and it aligns exactly with the guidance reset. Margins tell a mixed story: gross margin has structurally improved from ~67.8% in Q3 2023 to a 71.1% TTM level, holding in a tight 69.5%–72.5% band for eight straight quarters — that is genuine operating leverage, not a blip. Operating margin, however, expanded from ~12.9% (Q1 2024) to a 16–19% range through 2025 and has since slipped back to 16.0% (Q1 2026) and 16.2% (Q2 2026), versus 18.7% in Q2 2025 — i.e., modest YoY compression as R&D ramps ($88.1M in Q2 2026 vs $73.4M a year ago). Reported net income is noisy (Q2 2024's $188.6M and Q2 2025's depressed $22.5M both reflect one-offs), so TTM GAAP EPS of $5.416 is the better read. Bottom line: high-quality, profitable growth, but the second derivative has turned negative and the burden is proving to be the Type 2 cohort, not Type 1.

On the numbers as of 2026-09-13, PODD looks cheap in absolute terms and extraordinarily cheap against its own history. At $131.96 the stock trades at 24.6x TTM EPS of $5.416, 20.3x next-FY consensus EPS of $6.503, 15.0x EV/EBITDA, 2.99x sales and 6.43x book, with a PEG of 0.417 and a 3.3% trailing free-cash-flow yield ($298M TTM FCF on a $9.14B market cap). For a business growing revenue 23.5% with a 71.1% gross margin and 13.6% ROIC, a low-20s forward multiple is objectively undemanding. Against its own 5-year average P/S of 11.43x, the current 2.99x is a ~74% de-rating — which is why the deterministic model labels it 'Cheap vs. its own history' (the 5-year average P/E of 1,140x is a statistical artifact of near-zero earnings years and should be ignored). The honest caveat: 'cheap vs. its own history' partly reflects that the market no longer believes this deserves a 60–90x forward multiple — the growth algorithm has shifted from ~30% toward the high-teens, and a de-rating of a decelerating growth stock can persist. At ~20x forward earnings with a 20% growth rate, the downside from multiple compression looks largely spent; the risk is now estimate revision, not further multiple collapse.

The price is no longer pricing in perfection — it is pricing in skepticism, and the question is whether that skepticism overshoots. A 63% drawdown on a company still growing 23.5% means the market has moved from 'priced for flawless Type 2 execution' to 'priced for barely-adequate execution.' At $131.96 the stock discounts roughly 20x the $6.50 FY2027 consensus EPS, a multiple that assumes no re-acceleration and continued skepticism. That creates asymmetric setup logic: if the November Q3 print shows U.S. Type 2 retention stabilizing and the guidance cut proves to be the low-water mark, FY2027 estimates are likely conservative and a re-rating toward the mid-20s multiple happens fast. If Q3 shows further retention deterioration, the estimates themselves fall and the stock breaks its $126.40 low — so the honest read is that this is an estimate-revision trade, not a multiple trade, from here. Note also the earnings-quality gap: Q2 2026 adjusted EPS of $1.66 versus GAAP diluted EPS of $1.37 means a material slice of 'earnings' is SBC and amortization, so the headline forward P/E is flattering relative to cash economics.

As of 2026-09-13, this is a confirmed downtrend, not a washout. RSI(14) sits at 32.75 — approaching oversold but still above the 30 threshold that often marks capitulation — while price is 8.62% below the 20-day SMA, 13.58% below the 50-day SMA and 36.04% below the 200-day SMA: a fully bearish stack with no sign of a base. Momentum is still negative and worsening (−10.52% over one week vs −9.03% over one month means the selling accelerated recently), and the stock closed at $134.68 the prior session before the −2.02% move that produced this snapshot, just ~4% above the $126.40 52-week low. Practical implication: an RSI near 33 plus a fresh 52-week-low test often produces a violent relief bounce, so a trader could nibble, but there is zero trend confirmation for an investor — the first real evidence of a bottom would be a reclaim of the 50-day SMA (roughly $152–153, i.e., ~15% above the current price) on rising volume. Until then, buying here is catching a falling knife.

• Medical device multiple compression: high-growth medtech names have been de-rated disproportionately by rate sensitivity and sector rotation away from long-duration growth, which magnifies company-specific missteps like PODD's.
• Type 2 AID reimbursement and penetration: ADA guidelines now recommend automated insulin delivery for insulin-using Type 2 patients, but baseline penetration remains below 5%, so the intermediate growth thesis depends on payer coverage expansion and clinician adoption that has not yet materialized at scale.
• Competitive intensity in AID: Tandem (Mobi), Medtronic (MiniMed 780G/Simplera) and others are pressing on both tubed and tubeless formats, pressuring pricing power and share assumptions in the exact segment (Type 2) Insulet needs to win.
• Long-run GLP-1 overhang: rising GLP-1 use could shrink the insulin-dependent population over a multi-year horizon, a structural question that weighs on terminal-value assumptions for the whole insulin delivery category.
• Geographic mix shift and FX/supply chain: international growth guidance was raised to 30–32% and Spain (the 26th commercial country) launched, which helps the growth rate but adds FX translation risk and execution complexity across manufacturing and distribution footprints.

• Q3 2026 earnings in early November 2026 — the single most important datapoint: whether U.S. Type 2 retention and utilization are stabilizing, or whether the 17–19% guidance needs to come down again.
• Omnipod 6 pipeline progress and next-generation algorithm/expanded CGM compatibility (including Abbott FreeStyle Libre 3 Plus), which could re-anchor the growth narrative on innovation rather than Type 2 retention.
• International expansion trajectory — Spain launch and the raised 30–32% international growth outlook could offset U.S. softness and re-frame the mix more favorably.
• Resolution or escalation of the medical device correction (MDC) shareholder class actions and quality remediation, which currently acts as a permanent multiple discount.
• Management insider conviction (CEO open-market purchase of ~$160,000 in late August) and potential institutional repositioning at depressed valuations, plus any strategic/M&A interest a $9.1B market cap and 63% drawdown might attract.

• Further U.S. Type 2 retention/utilization deterioration forcing a second guidance cut — the specific failure mode the August reset only partially priced.
• Competitive share loss and pricing pressure in AID from Tandem and Medtronic, which would compress the 71% gross margin that currently underpins the whole quality case.
• Earnings-quality and dilution risk: Q2 2026 adjusted EPS of $1.66 versus GAAP diluted EPS of $1.37 means a large SBC/amortization wedge, and buybacks are not offsetting it, so GAAP earnings power is materially lower than the multiple implies.
• Persistent litigation and regulatory scrutiny stemming from the earlier voluntary medical device corrections, which could add cost, management distraction or new disclosure risk.
• Value-trap risk: the stock is 'cheap vs. its own history' precisely because it is being repriced from a ~30%-growth to a ~high-teens-growth asset; if terminal growth normalizes, today's 20x forward can still be too high, and a resumption of dividend-style institutional selling into any bounce would confirm that.

Insulet is a high-quality, cash-generative medtech franchise having a bad year, not a broken one: revenue grew 23.5% YoY in Q2 2026, gross margin is 71.1%, ROIC is 13.6%, leverage has fallen (long-term debt down to $929.5M against $534.9M cash), and the stock now trades at ~20x forward EPS with a 0.42 PEG — arguments you could not have made at $354 a share. But the specific problem is real and unresolved: U.S. Type 2 retention is worse than management expected, guidance was cut, sell-side conviction has cracked, and the technical picture shows a stock 36% below its 200-day SMA with no base. At $131.96 the risk/reward has shifted from hostile to roughly balanced, which is a genuine improvement, but there is no catalyst to force a re-rating before November. This is a watchlist name with a defined trigger — stabilization in the Q3 print — not a buy today.

I applied a 24x forward P/E to the next-FY (FY2027) consensus EPS of $6.503, giving $156.00: a mid-20s multiple is justified by ~20% guided revenue growth, a 71.1% gross margin and 13.6% ROIC, but is set at a discount to high-growth medtech peers (~30x) and to Insulet's own historical forward multiple range because of Type 2 retention volatility, competitive pressure and the GAAP-vs-adjusted earnings gap (Q2 2026: $1.37 GAAP vs $1.66 adjusted) — I cross-checked it with an 18x forward EV/EBITDA on ~$715M FY2027 EBITDA less ~$395M net debt, which lands near $180, so $156 sits deliberately toward the conservative end of my two methods rather than echoing the $185 analyst consensus.